Raily Aesthetic Medicine International Holdings Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022

In its 2023 reporting, Raily Aesthetic Medicine International Holdings Limited disclosed greenhouse gas emissions of 1.4K tCO2e/year. By scope: Scope 1: 19 tCO2e/year; Scope 2: 1.1K tCO2e/year; Scope 3: 14 tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
1.4K tCO2e/year
2023
💧
Water Usage
9.7K m3/year
2023
♻️
Waste
73 tonnes/year (non-hazardous), 7 tonnes/year (hazardous)
2023
⚙️
Energy Use
1.7K MWh/year
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).19 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.1.1K tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).14 tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20231.4K tCO2e/year
20221.1K tonnes of carbon dioxide equivalent

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce emissions of air pollutants, wastewater and waste by 3% by 2026.

📅 Medium-term

  • Reduce electricity and water consumption by 2% by 2026.

🌱 ESG Focus Areas

Environmental ProtectionEmployee ManagementOperating PracticesCommunity InvestmentAnti-corruption

⚠️ Challenges & Risks +

  • Business affected by the COVID-19 pandemic in the first month of 2023.
  • Intensified industry competition.
  • Downward trend in Jiumei Xinhe’s performance.
  • Delayed product launch cycle for Biotrisse.
  • Lack of medical liability insurance.

📋 Report Information

Reporting Period: 2023
Frameworks: Appendix C2 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited